Associate VP, Head of Development jobs in United States
cer-icon
Apply on Employer Site
company-logo

Agilent Technologies · 6 hours ago

Associate VP, Head of Development

Agilent Technologies is a leader in the development of oligonucleotide drug substance manufacturing. The Associate VP, Head of Development will oversee a department of scientists, manage manufacturing processes, and ensure compliance with client and regulatory standards.

BiotechnologyHealth CareHealth DiagnosticsLife SciencePharmaceutical
check
Culture & Values
check
H1B Sponsor Likelynote

Responsibilities

Responsible for overseeing the optimization, scale-up, and validation of manufacturing processes for oligonucleotide APIs that support investigational therapies as such therapies advance through the drug development life cycle
Provide regular interface with Agilent's clients for the purpose of technical goal alignment, project technical updates, and project status
Serve as the scientific ambassador of Agilent's Nucleic Acid Solutions Division to the world-wide BioPharma community by giving technical talks at industry trade shows and webinars, as well as authoring scientific publications including patents as applicable
Lead continuous improvement initiatives by innovating and/or collaborating on next generation manufacturing and analytical techniques for producing oligonucleotide drug substances
Support employee development, deliver feedback, evaluate performance, and ensure staff are trained in technical, scientific, regulatory, developmental, and GMP areas
Create a collaborative work culture that values teamwork, innovation, open communication, and a strong work ethic

Qualification

Ph.D. in chemistryDrug substance developmentGMP production experiencePharmaceutical developmentQuality by Design principlesDesign of Experiments (DOE)Analytical instrumentsRegulatory standards knowledgeTeam leadershipPublic speakingProject managementCollaboration

Required

Ph.D. in synthetic organic chemistry, biochemistry, or a master's degree in chemical engineering or a related discipline
Ten years of experience in drug substance development within GMP production settings
Five years leading teams composed of scientists, chemists, or engineers
Advanced proficiency in pharmaceutical development, successfully transferring safe, efficient, and scalable processes and testing protocols for API preparation and analysis
Skilled in formulating and articulating departmental objectives and strategies
Experienced in working closely with Agilent clients to customize solutions for their specific program requirements
Proficient at managing tight deadlines and consistently delivering projects on schedule
Adept at applying Quality by Design and Quality Risk Management principles to the development of drug substance processes
Expertise in Design of Experiments (DOE), Process Acceptable Ranges (PAR), and statistical process control, with knowledge of PAT tools and Quality by Design practices
Extensive hands-on experience with HPLC, GC-MS, LC-MS, MS-MS, NMR, and other analytical instruments used in chemical research
Competent in electronic databases, and literature and patent search platforms like SciFinder
Thorough understanding of regulatory standards including ICH Q7 and GMP compliance requirements
Background in public speaking, technical presentations, and sharing innovative developments in process or chemical research

Benefits

Eligibility for bonus
Stock
Benefits

Company

Agilent Technologies

company-logo
Agilent Technologies addresses the scientific and laboratory management needs of analytical scientists and clinical researchers.

H1B Sponsorship

Agilent Technologies has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (51)
2024 (56)
2023 (58)
2022 (70)
2021 (64)
2020 (53)

Funding

Current Stage
Public Company
Total Funding
$500M
2019-09-05Post Ipo Debt· $500M
1999-11-26IPO

Leadership Team

leader-logo
Mike McMullen
CEO and President
linkedin
leader-logo
Padraig McDonnell
President and CEO
linkedin
Company data provided by crunchbase